

Robert C Doebele

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/827148/publications.pdf>

Version: 2024-02-01

164
papers

23,250
citations

17405

63
h-index

8370

147
g-index

170
all docs

170
docs citations

170
times ranked

20896
citing authors

#	ARTICLE	IF	CITATIONS
1	Efficacy of Larotrectinib in <i>TRK</i> -Fusion-Positive Cancers in Adults and Children. <i>New England Journal of Medicine</i> , 2018, 378, 731-739.	13.9	2,036
2	Crizotinib in <i>ROS1</i> -Rearranged Non-Small-Cell Lung Cancer. <i>New England Journal of Medicine</i> , 2014, 371, 1963-1971.	13.9	1,656
3	Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 2 trials. <i>Lancet Oncology</i> , The, 2020, 21, 271-282.	5.1	1,034
4	Mechanisms of Resistance to Crizotinib in Patients with <i>ALK</i> Gene Rearranged Non-Small Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2012, 18, 1472-1482.	3.2	1,018
5	Non-Small Cell Lung Cancer, Version 5.2017, NCCN Clinical Practice Guidelines in Oncology. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2017, 15, 504-535.	2.3	994
6	Local Consolidative Therapy Vs. Maintenance Therapy or Observation for Patients With Oligometastatic Non-Small-Cell Lung Cancer: Long-Term Results of a Multi-Institutional, Phase II, Randomized Study. <i>Journal of Clinical Oncology</i> , 2019, 37, 1558-1565.	0.8	882
7	Local consolidative therapy versus maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer without progression after first-line systemic therapy: a multicentre, randomised, controlled, phase 2 study. <i>Lancet Oncology</i> , The, 2016, 17, 1672-1682.	5.1	865
8	Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring <i>ALK</i> gene rearrangement: a retrospective analysis. <i>Lancet Oncology</i> , The, 2011, 12, 1004-1012.	5.1	847
9	Safety and Antitumor Activity of the Multitargeted Pan- <i>TRK</i> , <i>ROS1</i> , and <i>ALK</i> Inhibitor Entrectinib: Combined Results from Two Phase I Trials (ALKA-372-001 and STARTRK-1). <i>Cancer Discovery</i> , 2017, 7, 400-409.	7.7	647
10	Rociletinib in <i>EGFR</i> -Mutated Non-Small-Cell Lung Cancer. <i>New England Journal of Medicine</i> , 2015, 372, 1700-1709.	13.9	615
11	Local Ablative Therapy of Oligoprogressive Disease Prolongs Disease Control by Tyrosine Kinase Inhibitors in Oncogene-Addicted Non-Small-Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2012, 7, 1807-1814.	0.5	585
12	Oncogenic and drug-sensitive NTRK1 rearrangements in lung cancer. <i>Nature Medicine</i> , 2013, 19, 1469-1472.	15.2	526
13	TRK-ing Down an Old Oncogene in a New Era of Targeted Therapy. <i>Cancer Discovery</i> , 2015, 5, 25-34.	7.7	509
14	Evolution and clinical impact of co-occurring genetic alterations in advanced-stage <i>EGFR</i> -mutant lung cancers. <i>Nature Genetics</i> , 2017, 49, 1693-1704.	9.4	423
15	Identifying and Targeting <i>ROS1</i> Gene Fusions in Non-Small Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2012, 18, 4570-4579.	3.2	405
16	Therapy-Induced Evolution of Human Lung Cancer Revealed by Single-Cell RNA Sequencing. <i>Cell</i> , 2020, 182, 1232-1251.e22.	13.5	371
17	Mechanisms and clinical activity of an <i>EGFR</i> and <i>HER2</i> exon 20-selective kinase inhibitor in non-small cell lung cancer. <i>Nature Medicine</i> , 2018, 24, 638-646.	15.2	351
18	Comparing and contrasting predictive biomarkers for immunotherapy and targeted therapy of NSCLC. <i>Nature Reviews Clinical Oncology</i> , 2019, 16, 341-355.	12.5	347

#	ARTICLE	IF	CITATIONS
19	An Oncogenic <i>NTRK</i> Fusion in a Patient with Soft-Tissue Sarcoma with Response to the Tropomyosin-Related Kinase Inhibitor LOXO-101. <i>Cancer Discovery</i> , 2015, 5, 1049-1057.	7.7	343
20	Optimizing the Detection of Lung Cancer Patients Harboring Anaplastic Lymphoma Kinase (<i>ALK</i>) Gene Rearrangements Potentially Suitable for <i>ALK</i> Inhibitor Treatment. <i>Clinical Cancer Research</i> , 2010, 16, 5581-5590.	3.2	325
21	Repotrectinib (TPX-0005) Is a Next-Generation <i>ROS1</i> / <i>TRK</i> / <i>ALK</i> Inhibitor That Potently Inhibits <i>ROS1</i> / <i>TRK</i> / <i>ALK</i> Solvent- Front Mutations. <i>Cancer Discovery</i> , 2018, 8, 1227-1236.	7.7	321
22	Molecular Pathways: <i>ROS1</i> Fusion Proteins in Cancer. <i>Clinical Cancer Research</i> , 2013, 19, 4040-4045.	3.2	310
23	Acral Lentiginous Melanoma Harboring a <i>ROS1</i> Gene Fusion With Clinical Response to Entrectinib. <i>JCO Precision Oncology</i> , 2017, 1, 1-7.	1.5	309
24	Entrectinib in <i>ROS1</i> fusion-positive non-small-cell lung cancer: integrated analysis of three phase 1² trials. <i>Lancet Oncology</i> , The, 2020, 21, 261-270.	5.1	303
25	Targeting <i>RET</i> in Patients With <i>RET</i> -Rearranged Lung Cancers: Results From the Global, Multicenter <i>RET</i> Registry. <i>Journal of Clinical Oncology</i> , 2017, 35, 1403-1410.	0.8	277
26	Oncogene status predicts patterns of metastatic spread in treatment-naïve nonsmall cell lung cancer. <i>Cancer</i> , 2012, 118, 4502-4511.	2.0	247
27	<i>RAS</i> - <i>MAPK</i> dependence underlies a rational polytherapy strategy in <i>EML4-ALK</i> positive lung cancer. <i>Nature Medicine</i> , 2015, 21, 1038-1047.	15.2	245
28	Phase II Trial of Stereotactic Body Radiation Therapy Combined With Erlotinib for Patients With Limited but Progressive Metastatic Non-Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2014, 32, 3824-3830.	0.8	244
29	Treating <i>ALK</i> -positive lung cancer² early successes and future challenges. <i>Nature Reviews Clinical Oncology</i> , 2012, 9, 268-277.	12.5	224
30	Pralsetinib for <i>RET</i> fusion-positive non-small-cell lung cancer (ARROW): a multi-cohort, open-label, phase 1/2 study. <i>Lancet Oncology</i> , The, 2021, 22, 959-969.	5.1	222
31	Anaplastic Lymphoma Kinase Gene Rearrangements in Non-small Cell Lung Cancer are Associated with Prolonged Progression-Free Survival on Pemetrexed. <i>Journal of Thoracic Oncology</i> , 2011, 6, 774-780.	0.5	221
32	Targeted Inhibition of the Molecular Chaperone Hsp90 Overcomes <i>ALK</i> Inhibitor Resistance in Non-Small Cell Lung Cancer. <i>Cancer Discovery</i> , 2013, 3, 430-443.	7.7	203
33	Stereotactic Radiation Therapy can Safely and Durably Control Sites of Extra-Central Nervous System Oligoprogressive Disease in Anaplastic Lymphoma Kinase-Positive Lung Cancer Patients Receiving Crizotinib. <i>International Journal of Radiation Oncology Biology Physics</i> , 2014, 88, 892-898.	0.4	182
34	Resistance Mechanisms to Targeted Therapies in <i>ROS1</i> + and <i>ALK</i> + Non-small Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2018, 24, 3334-3347.	3.2	182
35	<i>HER2</i> exon 20 insertions in non-small-cell lung cancer are sensitive to the irreversible pan- <i>HER</i> receptor tyrosine kinase inhibitor pyrotinib. <i>Annals of Oncology</i> , 2019, 30, 447-455.	0.6	151
36	A framework for understanding and targeting residual disease in oncogene-driven solid cancers. <i>Nature Medicine</i> , 2016, 22, 472-478.	15.2	145

#	ARTICLE	IF	CITATIONS
37	Identifying the Appropriate FISH Criteria for Defining MET Copy Number-Driven Lung Adenocarcinoma through Oncogene Overlap Analysis. <i>Journal of Thoracic Oncology</i> , 2016, 11, 1293-1304.	0.5	143
38	Clinical Utility of Cell-Free DNA for the Detection of <i>ALK</i> Fusions and Genomic Mechanisms of ALK Inhibitor Resistance in Non-Small Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2018, 24, 2758-2770.	3.2	143
39	Current Status and Future Perspectives on Neoadjuvant Therapy in Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2018, 13, 1818-1831.	0.5	133
40	Rapidly Acquired Resistance to EGFR Tyrosine Kinase Inhibitors in NSCLC Cell Lines through De-Repression of FGFR2 and FGFR3 Expression. <i>PLoS ONE</i> , 2010, 5, e14117.	1.1	130
41	Comparison of Molecular Testing Modalities for Detection of ROS1 Rearrangements in a Cohort of Positive Patient Samples. <i>Journal of Thoracic Oncology</i> , 2018, 13, 1474-1482.	0.5	130
42	Molecularly Targeted Therapies in Non-Small-Cell Lung Cancer Annual Update 2014. <i>Journal of Thoracic Oncology</i> , 2015, 10, S1-S63.	0.5	119
43	The Incidence of Brain Metastases in Stage IV ROS1-Rearranged Non-Small Cell Lung Cancer and Rate of Central Nervous System Progression on Crizotinib. <i>Journal of Thoracic Oncology</i> , 2018, 13, 1717-1726.	0.5	119
44	Resistance to ROS1 Inhibition Mediated by EGFR Pathway Activation in Non-Small Cell Lung Cancer. <i>PLoS ONE</i> , 2013, 8, e82236.	1.1	116
45	Clinicopathologic Features of Non-Small-Cell Lung Cancer Harboring an <i>NTRK</i> Gene Fusion. <i>JCO Precision Oncology</i> , 2018, 2018, 1-12.	1.5	112
46	Determination of the HLA-DM Interaction Site on HLA-DR Molecules. <i>Immunity</i> , 2000, 13, 517-527.	6.6	110
47	Larotrectinib in adult patients with solid tumours: a multi-centre, open-label, phase I dose-escalation study. <i>Annals of Oncology</i> , 2019, 30, 325-331.	0.6	110
48	Natural History and Factors Associated with Overall Survival in Stage IV ALK-Rearranged Non-Small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2019, 14, 691-700.	0.5	108
49	<i>ROS1</i> and <i>ALK</i> Fusions in Colorectal Cancer, with Evidence of Intratumoral Heterogeneity for Molecular Drivers. <i>Molecular Cancer Research</i> , 2014, 12, 111-118.	1.5	104
50	Dramatic Response to Crizotinib in a Patient With Lung Cancer Positive for an <i>HLA-DRB1-MET</i> Gene Fusion. <i>JCO Precision Oncology</i> , 2017, 2017, 1-6.	1.5	103
51	Interaction of HLA-DR with an Acidic Face of HLA-DM Disrupts Sequence-Dependent Interactions with Peptides. <i>Immunity</i> , 2003, 19, 183-192.	6.6	93
52	Accessory molecules for MHC class II peptide loading. <i>Current Opinion in Immunology</i> , 2000, 12, 99-106.	2.4	90
53	Correlations between the percentage of tumor cells showing an anaplastic lymphoma kinase (ALK) gene rearrangement, ALK signal copy number, and response to crizotinib therapy in ALK fluorescence in situ hybridization-positive nonsmall cell lung cancer. <i>Cancer</i> , 2012, 118, 4486-4494.	2.0	88
54	A Phase I/II Trial of the VEGFR-Sparing Multikinase RET Inhibitor RXDX-105. <i>Cancer Discovery</i> , 2019, 9, 384-395.	7.7	88

#	ARTICLE	IF	CITATIONS
55	Triple Angiokinase Inhibitor Nintedanib Directly Inhibits Tumor Cell Growth and Induces Tumor Shrinkage via Blocking Oncogenic Receptor Tyrosine Kinases. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2018, 364, 494-503.	1.3	85
56	Rapid onset hypogonadism secondary to crizotinib use in men with metastatic nonsmall cell lung cancer. <i>Cancer</i> , 2012, 118, 5302-5309.	2.0	84
57	PrlA and PrlG suppressors reduce the requirement for signal sequence recognition. <i>Journal of Bacteriology</i> , 1994, 176, 5607-5614.	1.0	80
58	Updated Integrated Analysis of the Efficacy and Safety of Entrectinib in Locally Advanced or Metastatic ROS1 Fusion Positive Non-Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2021, 39, 1253-1263.	0.8	74
59	Activation of RAS family members confers resistance to ROS1 targeting drugs. <i>Oncotarget</i> , 2015, 6, 5182-5194.	0.8	72
60	An Activating KIT Mutation Induces Crizotinib Resistance in ROS1-Positive Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2016, 11, 1273-1281.	0.5	71
61	Exploratory analysis of the association of depth of response and survival in patients with metastatic non-small-cell lung cancer treated with a targeted therapy or immunotherapy. <i>Annals of Oncology</i> , 2017, 28, 2707-2714.	0.6	70
62	A phase I, open-label dose-escalation study of continuous treatment with BIBF 1120 in combination with paclitaxel and carboplatin as first-line treatment in patients with advanced non-small-cell lung cancer. <i>Annals of Oncology</i> , 2012, 23, 2094-2102.	0.6	68
63	Diagnostic assays for identification of anaplastic lymphoma kinase-positive non-small cell lung cancer. <i>Cancer</i> , 2013, 119, 1467-1477.	2.0	68
64	Do More With Less: Tips and Techniques for Maximizing Small Biopsy and Cytology Specimens for Molecular and Ancillary Testing: The University of Colorado Experience. <i>Archives of Pathology and Laboratory Medicine</i> , 2016, 140, 1206-1220.	1.2	68
65	Resistance to RET-Inhibition in RET-Rearranged NSCLC Is Mediated By Reactivation of RAS/MAPK Signaling. <i>Molecular Cancer Therapeutics</i> , 2017, 16, 1623-1633.	1.9	66
66	EGFR Mediates Responses to Small-Molecule Drugs Targeting Oncogenic Fusion Kinases. <i>Cancer Research</i> , 2017, 77, 3551-3563.	0.4	65
67	Analysis of Cell-Free DNA from 32,989 Advanced Cancers Reveals Novel Co-occurring Activating RET Alterations and Oncogenic Signaling Pathway Aberrations. <i>Clinical Cancer Research</i> , 2019, 25, 5832-5842.	3.2	64
68	Targeted Therapies in Non-Small Cell Lung Cancer: Emerging Oncogene Targets Following the Success of Epidermal Growth Factor Receptor. <i>Seminars in Oncology</i> , 2014, 41, 110-125.	0.8	60
69	Anthrax Edema Toxin Inhibits Endothelial Cell Chemotaxis via Epac and Rap1. <i>Journal of Biological Chemistry</i> , 2007, 282, 19781-19787.	1.6	59
70	New strategies to overcome limitations of reversible EGFR tyrosine kinase inhibitor therapy in non-small cell lung cancer. <i>Lung Cancer</i> , 2010, 69, 1-12.	0.9	59
71	Differential Subcellular Localization Regulates Oncogenic Signaling by ROS1 Kinase Fusion Proteins. <i>Cancer Research</i> , 2019, 79, 546-556.	0.4	59
72	Phase 2, randomized, open-label study of ramucirumab in combination with first-line pemetrexed and platinum chemotherapy in patients with nonsquamous, advanced/metastatic non-small cell lung cancer. <i>Cancer</i> , 2015, 121, 883-892.	2.0	58

#	ARTICLE	IF	CITATIONS
73	ROS1 Gene Rearrangements Are Associated With an Elevated Risk of Peridiagnosis Thromboembolic Events. <i>Journal of Thoracic Oncology</i> , 2019, 14, 596-605.	0.5	56
74	Tarloxotinib Is a Hypoxia-Activated Pan-HER Kinase Inhibitor Active Against a Broad Range of HER-Family Oncogenes. <i>Clinical Cancer Research</i> , 2021, 27, 1463-1475.	3.2	52
75	A Phase I/II Study of Erlotinib in Combination with the Anti-Insulin-Like Growth Factor-1 Receptor Monoclonal Antibody IMC-A12 (Cixutumumab) in Patients with Advanced Non-small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2012, 7, 419-426.	0.5	48
76	Excellent Outcomes with Radiosurgery for Multiple Brain Metastases in ALK and EGFR Driven Non-Small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2018, 13, 715-720.	0.5	48
77	A Changing of the Guard: Immune Checkpoint Inhibitors With and Without Chemotherapy as First Line Treatment for Metastatic Non-small Cell Lung Cancer. <i>Frontiers in Oncology</i> , 2019, 9, 195.	1.3	48
78	Adding to the Mix: Fibroblast Growth Factor and Platelet-Derived Growth Factor Receptor Pathways as Targets in Non-small Cell Lung Cancer. <i>Current Cancer Drug Targets</i> , 2012, 12, 107-123.	0.8	47
79	Native and rearranged ALK copy number and rearranged cell count in non-small cell lung cancer. <i>Cancer</i> , 2013, 119, 3968-3975.	2.0	47
80	A Phase II, Open-Label Study of Ramucirumab in Combination with Paclitaxel and Carboplatin as First-Line Therapy in Patients with Stage IIIB/IV Non-Small-Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2014, 9, 1532-1539.	0.5	47
81	Symptomatic reduction in free testosterone levels secondary to crizotinib use in male cancer patients. <i>Cancer</i> , 2013, 119, 2383-2390.	2.0	45
82	A novel interplay between Epac/Rap1 and mitogen-activated protein kinase kinase 5/extracellular signal-regulated kinase 5 (MEK5/ERK5) regulates thrombospondin to control angiogenesis. <i>Blood</i> , 2009, 114, 4592-4600.	0.6	43
83	ALK Inhibitor Response in Melanomas Expressing EML4-ALK Fusions and Alternate ALK Isoforms. <i>Molecular Cancer Therapeutics</i> , 2018, 17, 222-231.	1.9	38
84	Novel Fc gamma receptor I family gene products in human mononuclear cells. <i>Journal of Clinical Investigation</i> , 1992, 90, 2102-2109.	3.9	38
85	Management of Brain Metastases in ALK-Positive Non-Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2016, 34, 2814-2819.	0.8	37
86	Randomized Phase II Trial of Seribantumab in Combination with Erlotinib in Patients with EGFR Wild-Type Non-Small Cell Lung Cancer. <i>Oncologist</i> , 2019, 24, 1095-1102.	1.9	37
87	Clinicopathologic Features and Response to Therapy of NRG1 Fusion-Driven Lung Cancers: The eNRGy1 Global Multicenter Registry. <i>Journal of Clinical Oncology</i> , 2021, 39, 2791-2802.	0.8	32
88	Novel glycosylation of HLA-DRalpha disrupts antigen presentation without altering endosomal localization. <i>Journal of Immunology</i> , 1998, 160, 4289-97.	0.4	31
89	Point Mutations in or Near the Antigen-Binding Groove of HLA-DR3 Implicate Class II-Associated Invariant Chain Peptide Affinity as a Constraint on MHC Class II Polymorphism. <i>Journal of Immunology</i> , 2003, 170, 4683-4692.	0.4	28
90	Cancer cell-intrinsic expression of MHC II in lung cancer cell lines is actively restricted by MEK/ERK signaling and epigenetic mechanisms. <i>Journal of Immunology</i> , 2020, 204, e000441.		28

#	ARTICLE	IF	CITATIONS
91	Acquired Resistance Is Oncogene and Drug Agnostic. <i>Cancer Cell</i> , 2019, 36, 347-349.	7.7	26
92	Clinicopathologic Characteristics, Treatment Outcomes, and Acquired Resistance Patterns of Atypical EGFR Mutations and HER2 Alterations in Stage IV Non-Small-Cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2020, 21, e191-e204.	1.1	26
93	Clinical Benefit From Pemetrexed Before and After Crizotinib Exposure and From Crizotinib Before and After Pemetrexed Exposure in Patients With Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2013, 14, 636-643.	1.1	25
94	ALK is a critical regulator of the MYC-signaling axis in ALK positive lung cancer. <i>Oncotarget</i> , 2018, 9, 8823-8835.	0.8	24
95	Aberrant intermolecular disulfide bonding in a mutant HLA-DM molecule: implications for assembly, maturation, and function. <i>Journal of Immunology</i> , 1998, 160, 734-43.	0.4	23
96	Non-malignant respiratory epithelial cells preferentially proliferate from resected non-small cell lung cancer specimens cultured under conditionally reprogrammed conditions. <i>Oncotarget</i> , 2017, 8, 11114-11126.	0.8	22
97	Preliminary Clinical and Molecular Analysis Results From a Single-Arm Phase 2 Trial of Brigatinib in Patients With Disease Progression After Next-Generation ALK Tyrosine Kinase Inhibitors in Advanced ALK+ NSCLC. <i>Journal of Thoracic Oncology</i> , 2021, 16, 156-161.	0.5	22
98	A tyrosine kinase inhibitor-induced interferon response positively associates with clinical response in EGFR-mutant lung cancer. <i>Npj Precision Oncology</i> , 2021, 5, 41.	2.3	22
99	Baseline and On-Treatment Characteristics of Serum Tumor Markers in Stage IV Oncogene-Addicted Adenocarcinoma of the Lung. <i>Journal of Thoracic Oncology</i> , 2018, 13, 134-138.	0.5	21
100	Malignant pleural disease is highly associated with subsequent peritoneal metastasis in patients with stage IV non-small cell lung cancer independent of oncogene status. <i>Lung Cancer</i> , 2016, 96, 27-32.	0.9	20
101	A Novel Interplay between Rap1 and PKA Regulates Induction of Angiogenesis in Prostate Cancer. <i>PLoS ONE</i> , 2012, 7, e49893.	1.1	20
102	Sunitinib combined with pemetrexed and cisplatin: results of a phase I dose-escalation and pharmacokinetic study in patients with advanced solid malignancies, with an expanded cohort in non-small cell lung cancer and mesothelioma. <i>Cancer Chemotherapy and Pharmacology</i> , 2013, 71, 307-319.	1.1	18
103	Abstract CT007: Entrectinib, an oral pan-Trk, ROS1, and ALK inhibitor in TKI-naïve patients with advanced solid tumors harboring gene rearrangements: Updated phase I results. <i>Cancer Research</i> , 2016, 76, CT007-CT007.	0.4	17
104	Neoadjuvant Oncogene-Targeted Therapy in Early Stage Non-Small-Cell Lung Cancer as a Strategy to Improve Clinical Outcome and Identify Early Mechanisms of Resistance. <i>Clinical Lung Cancer</i> , 2016, 17, 466-469.	1.1	16
105	Targeted therapies for ROS1-rearranged non-small cell lung cancer. <i>Drugs of Today</i> , 2019, 55, 641.	0.7	16
106	Activity of tarloxotinib in cells with EGFR exon20 insertion mutations and mechanisms of acquired resistance. <i>Thoracic Cancer</i> , 2021, 12, 1511-1516.	0.8	15
107	ALK gene rearrangements in unselected caucasians with non-small cell lung carcinoma (NSCLC). <i>Journal of Clinical Oncology</i> , 2010, 28, 10533-10533.	0.8	15
108	Long-Term Efficacy and Safety of Entrectinib in ROS1 Fusion-Positive NSCLC. <i>JTO Clinical and Research Reports</i> , 2022, 3, 100332.	0.6	15

#	ARTICLE	IF	CITATIONS
109	Genetic Testing for Lung Cancer: Reflex Versus Clinical Selection. <i>Journal of Clinical Oncology</i> , 2011, 29, 1943-1945.	0.8	14
110	Abstract CT060: STARTRK-2: A global phase 2, open-label, basket study of entrectinib in patients with locally advanced or metastatic solid tumors harboring TRK, ROS1, or ALK gene fusions. <i>Cancer Research</i> , 2017, 77, CT060-CT060.	0.4	13
111	Acquired Resistance to Targeted Therapies in Advanced Non-Small Cell Lung Cancer: New Strategies and New Agents. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2013, , e272-e278.	1.8	12
112	The Minority Report: Targeting the Rare Oncogenes in NSCLC. <i>Current Treatment Options in Oncology</i> , 2014, 15, 644-657.	1.3	12
113	Development of syngeneic murine cell lines for use in immunocompetent orthotopic lung cancer models. <i>Cancer Cell International</i> , 2020, 20, 417.	1.8	12
114	Comparative effectiveness analysis between entrectinib clinical trial and crizotinib real-world data in ROS1+ NSCLC. <i>Journal of Comparative Effectiveness Research</i> , 2021, 10, 1271-1282.	0.6	12
115	Acquired Resistance to Targeted Therapies in Advanced Non-Small Cell Lung Cancer: New Strategies and New Agents. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2013, 33, e272-e278.	1.8	12
116	Duration of Targeted Therapy in Patients With Advanced Non-small-cell Lung Cancer Identified by Circulating Tumor DNA Analysis. <i>Clinical Lung Cancer</i> , 2020, 21, 545-552.e1.	1.1	11
117	Targeting ALK, ROS1, and BRAF Kinases. <i>Journal of Thoracic Oncology</i> , 2012, 7, S375-S376.	0.5	10
118	Abstract 4529: Pharmacokinetics (PK) of LOXO-101 during the first-in-human Phase I study in patients with advanced solid tumors: Interim update. <i>Cancer Research</i> , 2015, 75, 4529-4529.	0.4	10
119	Crizotinib for the treatment of patients with advanced non-small cell lung cancer. <i>Drugs of Today</i> , 2012, 48, 271.	0.7	10
120	Pre- and post-treatment blood-based genomic landscape of patients with ROS1 or NTRK fusion-positive solid tumours treated with entrectinib. <i>Molecular Oncology</i> , 2022, 16, 2000-2014.	2.1	10
121	High dose acetaminophen inhibits STAT3 and has free radical independent anti-cancer stem cell activity. <i>Neoplasia</i> , 2021, 23, 348-359.	2.3	9
122	The Evolution of Tumor Classification: A Role for Genomics?. <i>Cancer Cell</i> , 2013, 24, 693-694.	7.7	8
123	EGFR Exon 19 Deletion Mutations and Systemic/Central Nervous System Miliary Metastasis: Clinical Correlations and Response to Therapy. <i>Clinical Lung Cancer</i> , 2014, 15, 387-389.	1.1	7
124	The Democratization of the Oncogene. <i>Cancer Discovery</i> , 2014, 4, 870-872.	7.7	7
125	Activity and mechanism of acquired resistance to tarloxotinib in HER2 mutant lung cancer: an in vitro study. <i>Translational Lung Cancer Research</i> , 2021, 10, 3659-3670.	1.3	7
126	Phase I open-label study of cediranib plus etoposide (E) and cisplatin (P) as first-line therapy for patients (pts) with small cell lung cancer (SCLC) or lung neuroendocrine cancer (NEC).. <i>Journal of Clinical Oncology</i> , 2010, 28, 7050-7050.	0.8	7

#	ARTICLE	IF	CITATIONS
127	GATA3 and MDM2 are synthetic lethal in estrogen receptor-positive breast cancers. <i>Communications Biology</i> , 2022, 5, 373.	2.0	7
128	Biomarkers Are Here to Stay for Clinical Research and Standard Care. <i>Journal of Thoracic Oncology</i> , 2010, 5, 1113-1115.	0.5	6
129	Oncogenic Fusions Involving Exon 19 of ALK. <i>Journal of Thoracic Oncology</i> , 2012, 7, e44.	0.5	6
130	Time to shift the burden of proof for oncogene-positive cancer?. <i>Nature Reviews Clinical Oncology</i> , 2013, 10, 492-493.	12.5	6
131	Erlotinib Response in an NSCLC Patient with a Novel Compound G719D+L861R Mutation in EGFR. <i>Journal of Thoracic Oncology</i> , 2013, 8, e83-e84.	0.5	6
132	A Nice Problem to Have: When ALK Inhibitor Therapy Works Better Than Expected. <i>Journal of Thoracic Oncology</i> , 2014, 9, 433-435.	0.5	6
133	Larotrectinib Is Highly Active in Patients With Advanced Recurrent TRK Fusion Thyroid (TC) and Salivary Gland Cancers (SGC). <i>International Journal of Radiation Oncology Biology Physics</i> , 2018, 100, 1318.	0.4	6
134	HLA Class I Binding of Mutant EGFR Peptides in NSCLC Is Associated With Improved Survival. <i>Journal of Thoracic Oncology</i> , 2021, 16, 104-112.	0.5	6
135	Novel Human-Derived RET Fusion NSCLC Cell Lines Have Heterogeneous Responses to RET Inhibitors and Differential Regulation of Downstream Signaling. <i>Molecular Pharmacology</i> , 2021, 99, 435-447.	1.0	6
136	Reply to M.C. Garassino et al. <i>Journal of Clinical Oncology</i> , 2011, 29, 3837-3838.	0.8	5
137	Re-examination of Maintenance Therapy in Non-Small Cell Lung Cancer with the Advent of New Anti-cancer Agents. <i>Drugs</i> , 2013, 73, 517-532.	4.9	5
138	Dramatic Response to Lorlatinib in a Patient With CD74-ROS1-Positive Lung Adenocarcinoma With Acquired F2004V Mutation. <i>JCO Precision Oncology</i> , 2019, 3, 1-6.	1.5	5
139	Evolution of MET and NRAS gene amplification as acquired resistance mechanisms in EGFR mutant NSCLC. <i>Npj Precision Oncology</i> , 2021, 5, 91.	2.3	5
140	Milademetan is a highly potent MDM2 inhibitor in Merkel cell carcinoma. <i>JCI Insight</i> , 2022, 7, .	2.3	5
141	Granulomatosis with polyangiitis in a patient treated with dabrafenib and trametinib for BRAF V600E positive lung adenocarcinoma. <i>BMC Cancer</i> , 2020, 20, 177.	1.1	4
142	P2.06-007 A Phase 1/2 Trial of the Oral EGFR/HER2 Inhibitor AP32788 in Non-Small Cell Lung Cancer (NSCLC). <i>Journal of Thoracic Oncology</i> , 2017, 12, S1072-S1073.	0.5	3
143	First-line Chemotherapy Responsiveness and Patterns of Metastatic Spread Identify Clinical Syndromes Present Within Advanced KRAS Mutant Non-Small-cell Lung Cancer With Different Prognostic Significance. <i>Clinical Lung Cancer</i> , 2018, 19, 531-543.	1.1	3
144	Cecal Volvulus as a Rare Complication of Osimertinib Dosed at 160 mg in Patients With EGFR-Mutant Non-small Cell Lung Cancer. <i>Frontiers in Oncology</i> , 2020, 10, 510.	1.3	3

#	ARTICLE	IF	CITATIONS
145	A time to test, a time to treat. <i>Journal of Thoracic Disease</i> , 2012, 4, 223-5.	0.6	3
146	Pharmacodynamic Studies in Early Phase Drug Development. , 2011, , 215-256.		2
147	Abstract LB-449: KRAS mutation and amplification status predicts sensitivity to antifolate therapies in non-small-cell lung cancer. , 2012, , .		2
148	Abstract LB-118: Identification of TRKA and TRKB kinase domain mutations that induce resistance to a pan-TRK inhibitor. , 2016, , .		2
149	Abstract 5233: Evolution of therapy resistance through acquired KRAS amplification in ROS1 fusion KRAS G12C double positive NSCLC. <i>Cancer Research</i> , 2022, 82, 5233-5233.	0.4	2
150	MA16.03 Global RET Registry (GLORY): Activity of RET-Directed Targeted Therapies in RET-Rearranged Lung Cancers. <i>Journal of Thoracic Oncology</i> , 2017, 12, S435-S436.	0.5	1
151	Abstract 3878: Bach1 promotes liver metastasis of colorectal cancer cells by regulating c-Myc and SOX4.. , 2013, , .		1
152	Final Results of a Phase 2, Open-Label Study of Ramucirumab (IMC-1121B; RAM), an IGG1 MAB Targeting Vegfr-2, with Paclitaxel and Carboplatin as First-Line Therapy in Patients (PTS) with Stage IIIB/IV Non-Small Cell Lung Cancer (NSCLC) (NCT00735696). <i>Annals of Oncology</i> , 2012, 23, ix422-ix423.	0.6	0
153	Rearranging Detection of Gene Rearrangements. <i>Journal of Thoracic Oncology</i> , 2015, 10, 1129-1130.	0.5	0
154	PS01.68: Heterogeneous Clinical Syndromes Existing Within Patients with Stage IV KRAS Mutant Non-Small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2016, 11, S313.	0.5	0
155	P1.02-057 Clinical Utility of ctDNA for Detecting ALK Fusions and Resistance Events in NSCLC: Analysis of a Laboratory Cohort. <i>Journal of Thoracic Oncology</i> , 2017, 12, S522.	0.5	0
156	Targeting Residual Disease in Oncogene-Driven NSCLC. <i>Journal of Thoracic Oncology</i> , 2017, 12, S1546.	0.5	0
157	Reply to J.K. Molitoris et al. <i>Journal of Clinical Oncology</i> , 2017, 35, 810-811.	0.8	0
158	The importance of the initial response to cancer treatment in predicting longer overall survival. <i>Expert Review of Clinical Pharmacology</i> , 2018, 11, 109-111.	1.3	0
159	Abstract 812: Lack of intra-tumoral heterogeneity in lung adenocarcinoma supports gene fusions involving ALK as early clonal events. , 2010, , .		0
160	Abstract 3467: A novel interplay between Rap1, Epac and PKA regulates induction of angiogenesis. , 2011, , .		0
161	Abstract 5594: ALK-driven lung cancer: Potential therapeutic strategies for treatment and prevention of drug resistance. , 2012, , .		0
162	Abstract 894: Targeting ROS1 receptor tyrosine kinase gene fusions in non-small cell lung cancer. , 2012, , .		0

#	ARTICLE	IF	CITATIONS
163	Abstract IA41: A new TRacK in lung cancer: NTRK1 gene fusions as a therapeutic target.. Clinical Cancer Research, 2014, 20, IA41-IA41.	3.2	0
164	Abstract 5255: EGFR is a conspiring kinase in gene fusion positive lung cancer. , 2014, , .		0